Related Experiment Video

Updated: May 8, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Teroxirone inhibited growth of human non-small cell lung cancer cells by activating p53

Jing-Ping Wang1, Kai-Han Lin, Chun-Yen Liu

  • 1Department of Life Science, National Taiwan Normal University, Taipei, Taiwan.

Toxicology and Applied Pharmacology
|August 20, 2013
PubMed

Insights

Teroxirone, an epoxide derivative, inhibits human non-small-cell lung cancer cell growth by inducing DNA damage and apoptosis. Its efficacy is dependent on p53 status, showing promise as a lung cancer therapeutic.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality.
  • Novel therapeutic strategies targeting cancer cell death pathways are urgently needed.
  • Understanding the role of tumor suppressor genes like p53 in drug response is critical.

Purpose of the Study:

  • To investigate the anti-cancer effects of teroxirone, an epoxide derivative, on human non-small-cell lung cancer (NSCLC) cells.
  • To elucidate the mechanism of teroxirone-induced cytotoxicity, focusing on apoptosis and the role of p53.
  • To evaluate the therapeutic potential of teroxirone in preclinical models of lung cancer.

Main Methods:

  • In vitro studies using NSCLC cell lines (H460, A549, H1299) treated with teroxirone.
  • Assessment of cell viability, apoptosis induction (DNA damage, caspase-3 cleavage), and p53 pathway activation (p53, p21).
  • In vivo studies using xenograft tumor models in nude mice to evaluate tumor growth suppression.

Main Results:

  • Teroxirone inhibited the growth of H460 and A549 NSCLC cells in vitro and suppressed xenograft tumor growth in vivo.
  • Cytotoxicity was mediated by p53-dependent apoptotic cell death, involving DNA damage and activation of p21 and caspase-3.
  • Drug sensitivity correlated with p53 status; wild-type p53 enhanced sensitivity, while mutant p53 or p53 knockdown reduced it.

Conclusions:

  • Teroxirone exhibits potent anti-cancer activity against NSCLC cells through p53-mediated apoptosis.
  • The drug's efficacy is linked to the functional status of the p53 pathway.
  • Teroxirone represents a promising therapeutic agent for NSCLC, particularly in tumors with intact p53 signaling.
Keywords:
ApoptosisHuman non-small-cell-lung-cancer cellsTeroxironep53

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...